Who Makes Wegovy? The Company, the Approval History, and What's Inside the Pen

Key Takeaways

• Wegovy is made by Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark.
• The active ingredient is semaglutide, the same drug Novo Nordisk sells under the brand name Ozempic for type 2 diabetes.
• The FDA approved Wegovy for chronic weight management in June 2021.
• Wegovy is filled and finished at Novo Nordisk plants in Denmark, France, and Clayton, North Carolina.
• The drug was developed in-house at Novo Nordisk and is patent-protected; no FDA-approved generic exists.

Direct answer (40-60 words)

Wegovy is made by Novo Nordisk, a Danish pharmaceutical company headquartered in Bagsværd, Denmark. Novo Nordisk also makes Ozempic and Rybelsus, both of which use the same active ingredient (semaglutide). The company has produced insulin and metabolic-disease medications for over 100 years and is one of the largest pharmaceutical companies in Europe.

Table of contents

1. The 30-second answer
2. About Novo Nordisk
3. How Wegovy was developed
4. FDA approval timeline for Wegovy
5. Where Wegovy is manufactured
6. What's actually inside a Wegovy pen
7. Wegovy vs Ozempic: same maker, different drug
8. Patents, generics, and compounded semaglutide
9. Pricing, supply, and the 2022 to 2024 shortage
10. FAQ
11. Sources
12. Footer disclaimers

About Novo Nordisk

Novo Nordisk A/S is a Danish multinational pharmaceutical company. It was formed in 1989 through the merger of two older Danish insulin makers, Nordisk Insulinlaboratorium (founded 1923) and Novo Terapeutisk Laboratorium (founded 1925). Both predecessor companies were among the first in Europe to commercialize insulin after Banting and Best's 1921 discovery.

A few things worth knowing about the company:

• Headquarters: Bagsværd, Denmark (greater Copenhagen).
• Listed on: Copenhagen Stock Exchange (NVO) and the New York Stock Exchange.
• Employees: roughly 70,000 globally as of 2025.
• Therapeutic focus: diabetes, obesity, hemophilia, growth disorders, and rare endocrine diseases. Diabetes and obesity together make up over 80% of revenue.
• Ownership structure: majority controlled by the Novo Nordisk Foundation, a Danish charitable foundation that funds biomedical research.

The company's diabetes franchise (insulin and GLP-1 receptor agonists) has been its largest revenue driver for decades. Wegovy and Ozempic together became the company's largest-selling products in 2023 and have remained so since.

How Wegovy was developed

Semaglutide, the active ingredient in Wegovy, was discovered and developed in-house at Novo Nordisk through the company's GLP-1 research program. The molecule was engineered as a long-acting analog of human GLP-1, a gut hormone that signals fullness after eating.

Native GLP-1 has a half-life of roughly 2 minutes in the bloodstream because an enzyme called DPP-4 cleaves it almost immediately. Novo Nordisk's chemists made three modifications to the GLP-1 amino acid sequence that extended the half-life to about 7 days:

1. Substituting alpha-aminoisobutyric acid (Aib) for alanine at position 8, which prevents DPP-4 cleavage.
2. Attaching a fatty acid (C18 di-acid) chain at position 26 via a glutamic acid linker, which lets the molecule bind reversibly to albumin in the blood. Albumin acts as a slow-release reservoir.
3. A second amino acid substitution at position 34 to prevent unintended fatty acid binding at that site.

The result is a peptide that activates the same GLP-1 receptors as the natural hormone but lasts a week per dose. That weekly half-life is why both Ozempic and Wegovy are once-weekly injections.

The same molecule is sold at lower doses (0.25 to 2 mg per week) for diabetes under the Ozempic brand and at higher doses (up to 2.4 mg per week) for weight management under the Wegovy brand.

FDA approval timeline for Wegovy

A simplified timeline of how Wegovy got to market in the United States:

The cardiovascular indication was a meaningful regulatory expansion. SELECT showed a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in patients on Wegovy compared to placebo, in a population that was overweight or obese but did not have diabetes.

For more on what Wegovy treats, see our GLP-1 medications overview.

Where Wegovy is manufactured

Wegovy is filled and finished at Novo Nordisk's own production facilities. The company has historically manufactured semaglutide-containing products at three primary sites:

• Kalundborg, Denmark. The largest semaglutide active pharmaceutical ingredient (API) production site, expanded multiple times since 2020. Most of the global semaglutide supply originates here.
• Chartres, France. Pen assembly and final-product filling.
• Clayton, North Carolina, USA. Pen assembly and filling for the U.S. market. Capacity has expanded with multi-billion-dollar investments announced in 2022 and 2023.

In 2024, Novo Nordisk's parent foundation acquired Catalent for roughly $16.5 billion, which gave Novo Nordisk three additional fill-finish manufacturing sites: Bloomington (Indiana, USA), Brussels (Belgium), and Anagni (Italy). These sites have been brought into the Wegovy supply chain to expand global capacity.

A pen sold to a U.S. patient typically has the API made in Denmark, the pen device assembled in either Denmark or France, and final fill-finish completed in North Carolina. The exact origin appears in small print on the carton.

What's actually inside a Wegovy pen

A single-dose Wegovy pen contains:

• Active ingredient: semaglutide, in one of six dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and a 2 mg starter dose, depending on the titration step)
• Solvent: sterile water for injection
• Buffer: disodium phosphate dihydrate (controls pH)
• Tonicity agent: propylene glycol (matches the solution's osmolality to body fluid)
• Preservative: phenol (allows the pen to be stored at room temperature for up to 28 days after first use)
• pH adjuster: hydrochloric acid and/or sodium hydroxide as needed during manufacturing

The pen itself is a single-patient-use, single-dose device. Each pen contains one weekly dose. After the injection, the entire pen goes in a sharps container.

This is different from the Ozempic pen, which is a multi-dose pen containing 4 doses' worth of solution and using a dose dial. The Wegovy device is mechanically simpler because each pen delivers a fixed pre-set dose.

Wegovy vs Ozempic: same maker, different drug?

Same active ingredient. Different brand. Different approved use. Different dose strengths.

The drug is identical at the molecule level. The brand difference is regulatory (different approved indications) and packaging (different pen formats and dose strengths). A doctor cannot legally prescribe Ozempic for weight loss using insurance billing under most circumstances, even though the drug is the same.

For more on this, see our Ozempic vs Wegovy comparison and our what is Ozempic guide.

Patents, generics, and compounded semaglutide

Novo Nordisk holds the U.S. patent for semaglutide. Composition-of-matter patents in the U.S. are scheduled to expire around 2031 to 2033, depending on which patent claim is invoked. After expiration, generic manufacturers can apply for FDA approval of generic semaglutide products.

Until then, no FDA-approved generic semaglutide exists. The only semaglutide products on the U.S. market are Novo Nordisk's branded products: Ozempic, Wegovy, and Rybelsus (oral semaglutide).

A separate category exists for compounded semaglutide. Compounded semaglutide is prepared by state-licensed compounding pharmacies, which are allowed to prepare drugs in patient-specific quantities and formulations under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide is not FDA-approved, has not been through the FDA's review process, and is not interchangeable with Wegovy or Ozempic.

The FDA placed semaglutide on its drug shortage list in 2022, which expanded the legal scope under which compounding pharmacies could prepare semaglutide. The shortage was officially declared resolved in February 2025, which limits the conditions under which 503A compounding of semaglutide can continue. 503B outsourcing facilities operate under a different regulatory framework with stricter manufacturing standards.

For more on the regulatory differences, see our why is my compounded semaglutide red guide.

Pricing, supply, and the shortage period

Wegovy launched in the U.S. with a list price of roughly $1,349 per 28-day supply (4 weekly pens). Insurance coverage for chronic weight management has expanded over time but remains inconsistent, and many patients pay cash.

Three things shaped Wegovy availability between 2021 and 2025:

• 2021 launch and immediate demand outstripping supply. Novo Nordisk paused new patient starts in late 2021 due to a manufacturing constraint at a contract filler.
• 2022 to 2024 shortage. The FDA listed semaglutide on its drug shortage list in March 2022. Both Ozempic and Wegovy were affected at various times. Novo Nordisk invested several billion dollars in manufacturing expansion at Kalundborg and Clayton.
• February 2025 shortage resolution. The FDA declared the semaglutide shortage resolved, which began the wind-down of mass 503A compounding. 503B outsourcing facilities have additional time and stricter rules.

As of 2026, all six Wegovy dose strengths are listed as available in the U.S. market. Pricing has remained near the launch list price, with manufacturer savings programs available to commercially insured patients.

FAQ

Who makes Wegovy? Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark, makes Wegovy. The same company makes Ozempic, Rybelsus, and a portfolio of insulin products.

Where is Wegovy manufactured? Wegovy active pharmaceutical ingredient is primarily made in Kalundborg, Denmark. Pens are filled and assembled at Novo Nordisk facilities in Denmark, France, North Carolina, and additional sites acquired from Catalent in 2024.

Is Wegovy made in the United States? Final assembly and fill-finish for the U.S. market is largely done at Novo Nordisk's Clayton, North Carolina facility. The active ingredient itself is most often produced in Denmark.

Is Wegovy a Novo Nordisk drug? Yes. Wegovy is owned, manufactured, and marketed by Novo Nordisk. It was developed in-house, not licensed from another company.

When was Wegovy FDA-approved? June 4, 2021, for chronic weight management. Approval was expanded to adolescents in December 2022 and to cardiovascular risk reduction in March 2024.

Is Wegovy the same as Ozempic? Same active ingredient (semaglutide). Different brand, different FDA-approved use, different dose strengths, different pen format. Wegovy is approved for weight management at doses up to 2.4 mg weekly. Ozempic is approved for diabetes and goes up to 2 mg weekly.

Is there a generic Wegovy? No. The semaglutide patent runs into the early 2030s. No FDA-approved generic exists. Compounded semaglutide is prepared by compounding pharmacies and is not FDA-approved.

Why is Wegovy so expensive? Wegovy is a patent-protected biologic. Insurance coverage for weight-management drugs has historically been limited, and the manufacturer prices to recoup R&D and manufacturing investment during the patent window. List price in 2026 is roughly $1,349 per 28-day supply.

Is Novo Nordisk a public company? Yes. Novo Nordisk is listed on the Copenhagen Stock Exchange (NVO) and the New York Stock Exchange. Majority control sits with the Novo Nordisk Foundation, a Danish charitable foundation.

Does Novo Nordisk make insulin too? Yes. Novo Nordisk has been making insulin since the 1920s and is one of the world's largest insulin producers. Ozempic and Wegovy come from the same company's GLP-1 research program that grew out of decades of metabolic disease work.

Can I get Wegovy from my regular pharmacy? Yes, with a prescription. Wegovy is dispensed through retail and specialty pharmacies in the U.S. Prior authorization is common because of cost.

Has Wegovy been recalled? No nationwide recall of Wegovy has occurred as of April 2026. Novo Nordisk and the FDA monitor manufacturing and adverse events continuously, and any recalls would be posted to the FDA Recalls page.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
3. FDA. Wegovy (semaglutide injection 2.4 mg) prescribing information. Approved June 4, 2021; current label revision 2024.
4. FDA Drug Shortage Database. Semaglutide injection products, listing and resolution records. Accessed Q1 2026.
5. Novo Nordisk Annual Report 2024. Bagsværd, Denmark.
6. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.